These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 21226700

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T, Fujimoto A, Nakao K, Saruta T, CASE-J Trial Group.
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T, CASE-J Ex Study Group.
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
    Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, Azuma J, Ogihara T, Saruta T, Nakao K, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.
    Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R, Mugellini A, Derosa G, CANDIA (CANdesartan and DIuretic vs. Amlodipine in hypertensive patients) Study Group.
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical implications from the results of the CASE-J extension].
    Yasuno S, Fujimoto A, Ueshima K.
    Nihon Rinsho; 2012 Mar; 70(3):519-27. PubMed ID: 22514936
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 18. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 19. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
    Matsuno Y, Minatoguchi S, Fujiwara H, GIFU Substudy Group of The Case-J Trial.
    Blood Press Suppl; 2011 Apr; 1():12-9. PubMed ID: 21247247
    [Abstract] [Full Text] [Related]

  • 20. The X-cellent Study.
    Safar ME.
    Am J Hypertens; 2006 Jan; 19(1):8-9. PubMed ID: 16461182
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.